Enoxaparin in ACS
Enoxaparin in ACS
Enoxaparin in ACS
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
NICE -3Objectiveso To assess the safety yp profile (primarily withrespect to bleed<strong>in</strong>g) of enoxapar<strong>in</strong> and a IIb/IIIaantagonist (abciximab, eptifibatide or tirofiban) <strong>in</strong>patients with <strong>ACS</strong>o To assess the feasibility and safety of br<strong>in</strong>g<strong>in</strong>gpatients t forward to the catheterization t ti laboratoryon comb<strong>in</strong>ation therapy (without the use of UFhepar<strong>in</strong>)NICE -3Protocol661 patients enrolledAll treated t with<strong>Enoxapar<strong>in</strong></strong>46 cl<strong>in</strong>ical sites <strong>in</strong>US / CanadaStudy Initiatedt January 2000[<strong>Enoxapar<strong>in</strong></strong>alone](n=45)Tirofiban(n=217)Eptifibatide(n=252)All IIb/IIIa patients(n=616)Abciximab(n=147)Enrollment CompletedMay 2000In-hospital, 14-day, and 30-day follow-upData availableAugust 2000
Change language